Prediagnostic Serum 25-Hydroxyvitamin D and Mortality Among Bladder Cancer Patients in the Janus Serum Bank Cohort

References

• BrayF, FerlayJ, SoerjomataramI, SiegelRL, TorreLA, JemalA. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• KucukU, PalaEE, CakırE, et al. Clinical, demographic and histopathological prognostic factors for urothelial carcinoma of the bladder. Cent Eur J Urol. 2015;68(1):30–36. doi:10.5173/ceju.2015.01.465
   Google Scholar
• HouL, HongX, DaiM, et al. Association of smoking status with prognosis in bladder cancer: a meta-analysis. Oncotarget. 2017;8(1):1278–1289. doi:10.18632/oncotarget.1360627902481
   PubMedGoogle Scholar
• KluthLA, XylinasE, CrivelliJJ, et al. Obesity is associated with worse outcomes in patients with T1 high grade urothelial carcinoma of the bladder. J Urol. 2013;190(2):480–486. doi:10.1016/j.juro.2013.01.08923376707
   PubMed Web of Science ®Google Scholar
• TheodoratouE, TzoulakiI, ZgagaL, IoannidisJPA. Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials. BMJ. 2014;348:g2035. doi:10.1136/bmj.g203524690624
   PubMed Web of Science ®Google Scholar
• SluyterJD, MansonJE, ScraggR. Vitamin D and clinical cancer outcomes: a review of meta-analyses. JBMR Plus. 2021;5:e10420. doi:10.1002/jbm4.1042033553987
   PubMedGoogle Scholar
• KeumN, LeeDH, GreenwoodDC, MansonJE, GiovannucciE. Vitamin D supplementation and total cancer incidence and mortality: a meta-analysis of randomized controlled trials. Ann Oncol. 2019;30(5):733–743. doi:10.1093/annonc/mdz05930796437
   PubMed Web of Science ®Google Scholar
• NairR, MaseehA. Vitamin D: the “sunshine” vitamin. J Pharmacol Pharmacother. 2012;3(2):118–126.22629085
   PubMedGoogle Scholar
• BikleDD. Vitamin D metabolism, mechanism of action, and clinical applications. Chem Biol. 2014;21(3):319–329. doi:10.1016/j.chembiol.2013.12.01624529992
   PubMedGoogle Scholar
• BikleD. Nonclassic actions of vitamin D. J Clin Endocrinol Metab. 2009;94(1):26–34. doi:10.1210/jc.2008-145418854395
   PubMed Web of Science ®Google Scholar
• VanoirbeekE, KrishnanA, EelenG, et al. The anti-cancer and anti-inflammatory actions of 1,25(OH)2D3. Best Pract Res Clin Endocrinol Metab. 2011;25(4):593–604. doi:10.1016/j.beem.2011.05.00121872801
   PubMed Web of Science ®Google Scholar
• ZhangY, FangF, TangJ, et al. Association between vitamin D supplementation and mortality: systematic review and meta-analysis. BMJ. 2019;366:l4673. doi:10.1136/bmj.l467331405892
   PubMed Web of Science ®Google Scholar
• ChandlerPD, ChenWY, AjalaON, et al. Effect of vitamin D3 supplements on development of advanced cancer: a secondary analysis of the VITAL randomized clinical trial. JAMA Netw Open. 2020;3(11):e2025850–e2025850. doi:10.1001/jamanetworkopen.2020.2585033206192
   PubMed Web of Science ®Google Scholar
• SchöttkerB, JordeR, PeaseyA, et al. Vitamin D and mortality: meta-analysis of individual participant data from a large consortium of cohort studies from Europe and the United States. BMJ. 2014;348:g3656. doi:10.1136/bmj.g365624938302
   PubMed Web of Science ®Google Scholar
• ChowdhuryR, KunutsorS, VitezovaA, et al. Vitamin D and risk of cause specific death: systematic review and meta-analysis of observational cohort and randomised intervention studies. BMJ. 2014;348:g1903. doi:10.1136/bmj.g190324690623
   PubMed Web of Science ®Google Scholar
• YinL, Ordóñez-MenaJM, ChenT, SchöttkerB, ArndtV, BrennerH. Circulating 25-hydroxyvitamin D serum concentration and total cancer incidence and mortality: a systematic review and meta-analysis. Prev Med. 2013;57(6):753–764. doi:10.1016/j.ypmed.2013.08.02624036014
   PubMed Web of Science ®Google Scholar
• AfzalS, Brøndum-JacobsenP, BojesenSE, NordestgaardBG. Genetically low vitamin D concentrations and increased mortality: Mendelian randomisation analysis in three large cohorts. BMJ. 2014;349:g6330. doi:10.1136/bmj.g633025406188
   PubMed Web of Science ®Google Scholar
• HanJ, GuoX, YuX, et al. 25-hydroxyvitamin D and total cancer incidence and mortality: a meta-analysis of prospective cohort studies. Nutrients. 2019;11(10):2295. doi:10.3390/nu11102295
   PubMed Web of Science ®Google Scholar
• Vaughan-ShawPG, O’SullivanF, FarringtonSM, et al. The impact of vitamin D pathway genetic variation and circulating 25-hydroxyvitamin D on cancer outcome: systematic review and meta-analysis. Br J Cancer. 2017;116(8):1092–1110. doi:10.1038/bjc.2017.4428301870
   PubMed Web of Science ®Google Scholar
• TretliS, HernesE, BergJP, HestvikUE, RobsahmTE. Association between serum 25(OH)D and death from prostate cancer. Br J Cancer. 2009;100(3):450–454. doi:10.1038/sj.bjc.660486519156140
   PubMed Web of Science ®Google Scholar
• RobsahmTE, TretliS, TorjesenPA, BabigumiraR, SchwartzGG. Serum 25-hydroxyvitamin D levels predict cancer survival: a prospective cohort with measurements prior to and at the time of cancer diagnosis. Clin Epidemiol. 2019;11:695–705. doi:10.2147/CLEP.S20723031496824
   PubMed Web of Science ®Google Scholar
• MondulAM, WeinsteinSJ, LayneTM, AlbanesD. Vitamin D and cancer risk and mortality: state of the science, gaps, and challenges. Epidemiol Rev. 2017;39(1):28–48. doi:10.1093/epirev/mxx00528486651
   PubMed Web of Science ®Google Scholar
• WeinsteinSJ, MondulAM, YuK, et al. Circulating 25-hydroxyvitamin D up to 3 decades prior to diagnosis in relation to overall and organ-specific cancer survival. Eur J Epidemiol. 2018;33(11):1087–1099. doi:10.1007/s10654-018-0428-230073448
   PubMed Web of Science ®Google Scholar
• Ben FradjMK, BibiM, HammamiMB, KallelA, NouiraY, FekiM. Low plasma 25-hydoxyvitamin D at diagnosis predicts poor outcomes in patients with bladder cancer: a prospective cohort study. Nutr Cancer. 2021;73(1):55–61. doi:10.1080/01635581.2020.173715032672109
   PubMed Web of Science ®Google Scholar
• PeirisAN, BaileyBA, ManningT. Relationship of vitamin D monitoring and status to bladder cancer survival in veterans. South Med J. 2013;106(2):126–130. doi:10.1097/SMJ.0b013e3182824d0023380747
   PubMed Web of Science ®Google Scholar
• FerrariD, LombardiG, BanfiG. Concerning the vitamin D reference range: pre-analytical and analytical variability of vitamin D measurement. Biochem Med (Zagreb). 2017;27(3):030501. doi:10.11613/BM.2017.03050128900363
   PubMed Web of Science ®Google Scholar
• RobsahmTE, SchwartzGG, TretliS. The inverse relationship between 25-hydroxyvitamin D and cancer survival: discussion of causation. Cancers (Basel). 2013;5(4):1439–1455. doi:10.3390/cancers504143924202453
   PubMedGoogle Scholar
• LangsethH, GislefossRE, MartinsenJI, DillnerJ, UrsinG. Cohort profile: the Janus Serum bank cohort in Norway. Int J Epidemiol. 2017;46(2):403–404g.27063606
   PubMed Web of Science ®Google Scholar
• HjerkindKV, GislefossRE, TretliS, et al. Cohort profile update: the Janus Serum bank cohort in Norway. Int J Epidemiol. 2017;46(4):1101–1102f.28087783
   PubMed Web of Science ®Google Scholar
• HektoenHH, RobsahmTE, StenehjemJS, et al. Vitamin D and vitamin D-binding protein and risk of bladder cancer: a nested case-control study in the Norwegian Janus Serum Bank Cohort. Cancer Med. 2021;10(12):4107–4116. doi:10.1002/cam4.396034080787
   PubMed Web of Science ®Google Scholar
• LarsenIK, SmastuenM, JohannesenTB, et al. Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer. 2009;45(7):1218–1231. doi:10.1016/j.ejca.2008.10.03719091545
   PubMed Web of Science ®Google Scholar
• HolickMF. Vitamin D status: measurement, interpretation, and clinical application. Ann Epidemiol. 2009;19(2):73–78. doi:10.1016/j.annepidem.2007.12.00118329892
   PubMed Web of Science ®Google Scholar
• LipsP, CashmanKD, Lamberg-AllardtC, et al. Current vitamin D status in European and Middle East countries and strategies to prevent vitamin D deficiency: a position statement of the European Calcified Tissue Society. Eur J Endocrinol. 2019;180(4):P23–P54.30721133
   PubMed Web of Science ®Google Scholar
• HarrellFE. General aspects of fitting regression models. In: Regression Modeling Strategies: With Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis. Cham: Springer International Publishing; 2015:13–44.
   Google Scholar
• GrantWB, GarlandCF. The association of solar ultraviolet B (UVB) with reducing risk of cancer: multifactorial ecologic analysis of geographic variation in age-adjusted cancer mortality rates. Anticancer Res. 2006;26(4A):2687–2699.16886679
   PubMed Web of Science ®Google Scholar
• BoscoeFP, SchymuraMJ. Solar ultraviolet-B exposure and cancer incidence and mortality in the United States, 1993–2002. BMC Cancer. 2006;6(1):264. doi:10.1186/1471-2407-6-26417096841
   PubMed Web of Science ®Google Scholar
• FanX, WangJ, SongM, et al. Vitamin D status and risk of all-cause and cause-specific mortality in a large cohort: results from the UK biobank. J Clin Endocrinol Metab. 2020;105(10):e3606–e3619. doi:10.1210/clinem/dgaa432
   Web of Science ®Google Scholar
• SchottkerB, HaugU, SchomburgL, et al. Strong associations of 25-hydroxyvitamin D concentrations with all-cause, cardiovascular, cancer, and respiratory disease mortality in a large cohort study. Am J Clin Nutr. 2013;97(4):782–793. doi:10.3945/ajcn.112.04771223446902
   PubMed Web of Science ®Google Scholar
• DurupD, JørgensenHL, ChristensenJ, SchwarzP, HeegaardAM, LindB. A reverse J-shaped association of all-cause mortality with serum 25-hydroxyvitamin D in general practice: the CopD study. J Clin Endocrinol Metab. 2012;97(8):2644–2652. doi:10.1210/jc.2012-117622573406
   PubMed Web of Science ®Google Scholar
• GrantWB, KarrasSN, Bischoff-FerrariHA, et al. Do studies reporting ‘U’-shaped serum 25-hydroxyvitamin D-health outcome relationships reflect adverse effects?Dermatoendocrinol. 2016;8(1):e1187349. doi:10.1080/19381980.2016.118734927489574
   PubMed Web of Science ®Google Scholar
• HeistRS, ZhouW, WangZ, et al. Circulating 25-hydroxyvitamin D, VDR polymorphisms, and survival in advanced non-small-cell lung cancer. J Clin Oncol. 2008;26(34):5596–5602. doi:10.1200/JCO.2008.18.040618936471
   PubMed Web of Science ®Google Scholar
• ZhouW, HeistRS, LiuG, et al. Circulating 25-hydroxyvitamin D levels predict survival in early-stage non-small-cell lung cancer patients. J Clin Oncol. 2007;25(5):479–485. doi:10.1200/JCO.2006.07.535817290055
   PubMed Web of Science ®Google Scholar
• American Society of Clinical Oncology.Bladder cancer: treatments by stage; 2021. Available from: https://www.cancer.net/cancer-types/bladder-cancer/treatments-stage. Accessed 830, 2021.
   Google Scholar
• HsuJ-W, YinP-N, WoodR, MessingJ, MessingE, LeeY-F. 1 alpha, 25-dihydroxylvitamin D3 promotes Bacillus Calmette-Guérin immunotherapy of bladder cancer. Oncotarget. 2013;4(12):2397–2406. doi:10.18632/oncotarget.149424353168
   PubMedGoogle Scholar
• LipsP, van SchoorNM, de JonghRT. Diet, sun, and lifestyle as determinants of vitamin D status. Ann N Y Acad Sci. 2014;1317(1):92–98. doi:10.1111/nyas.1244324814938
   PubMed Web of Science ®Google Scholar
• HofmannJN, YuK, HorstRL, HayesRB, PurdueMP. Long-term variation in serum 25-hydroxyvitamin D concentration among participants in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev. 2010;19(4):927–931. doi:10.1158/1055-9965.EPI-09-112120332255
   PubMed Web of Science ®Google Scholar
• HaddadJG. Plasma vitamin D-binding protein (Gc-globulin): multiple tasks. J Steroid Biochem Mol Biol. 1995;53(1–6):579–582. doi:10.1016/0960-0760(95)00104-87626513
   PubMed Web of Science ®Google Scholar
• Helsebiblioteket.National guidelines bladder cancer treatment; 2021. Available from: https://www.helsebiblioteket.no/retningslinjer/bl%C3%A6rekreft/utgivelsesinformasjon. Accessed 830, 2021.
   Google Scholar